查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1857525

支气管扩张治疗市场：2025-2032年全球预测（按药物类型、给药途径、病患族群、支气管扩张类型及分销管道划分）

Bronchiectasis Drugs Market by Drug Type, Route Of Administration, Patient Demographics, Bronchiectasis Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，支气管扩张药物市场将成长至 31.3 亿美元，复合年增长率为 9.46%。

关键市场统计数据
基准年 2024 15.2亿美元
预计年份：2025年 16.5亿美元
预测年份 2032 31.3亿美元
复合年增长率 (%) 9.46%

本书对支气管扩张药物治疗的发展、临床重点以及不断演变的治疗创新框架进行了简明扼要且权威的说明。

由于诊断意识的提高、治疗假设的拓展以及对生活品质日益重视，支气管扩张症已从临床上的默默无闻转变为药物研发的重点。近年来，抗发炎策略、标靶抗菌疗法、气道清除方法以及症状性支气管扩张症的研究，与影像学、痰液微生物学和纵向患者登记技术的进步相融合。临床见解与转化科学的这种融合，使临床医生和相关人员能够将气喘视为一种可治疗的慢性疾病，而非一种不可避免的进行性疾病。

因此，目前研发管线涵盖了现有药物的再利用、新型化合物以及旨在解决支气管扩张多因子病理生理机制的递送优化製剂。患者报告结局和减少急性加重次数正日益成为监管对话中的关键终点，而支付方和医疗服务提供方则关注那些能够显着降低医疗资源利用率并改善患者日常生活功能的治疗方法。因此，策略决策需要综合考虑临床证据、治疗差异化以及实际实施障碍，才能将科学进步转化为永续的患者获益。

深入说明标靶免疫调节、个人化治疗和给药创新如何重塑支气管扩张的治疗模式

支气管扩张的治疗方法正在经历深刻的变革，这主要得益于靶向免疫调节、精准抗生素管理和吸入给药系统等领​​域的创新。首先，超越广泛使用皮质类固醇的抗发炎策略的出现，包括选择性通路调节剂和辅助药物，重塑了治疗模式，使其优先控制慢性炎症，同时避免不可接受的全身暴露。这种转变，加上对气道微生物组动态变化更深入的理解，正在推动旨在降低病原体负荷并维持微生物生态系统的抗生素和生物製药的研发。

同时，器械和製剂主导的进步，例如吸入製剂和优化的雾化器技术，提高了局部药物浓度和耐受性，从而减少了长期治疗的阻力。在监管和循证方面，相关人员目前优先考虑以患者为中心的终点指标，例如病情加重频率、功能能力和健康相关的生活质量，这正在影响临床试验设计和上市后价值论证。总而言之，这些转变正在推动支气管扩张症管理朝着以患者为中心、精准化的方向发展，使临床目标与产品创新和推广路径保持一致。

本文从实际角度探讨了美国近期关税政策变化如何影响呼吸系统治疗药物供应链的韧性、采购调整和筹资策略转变。

美国近期关税政策的变化为呼吸系统药物的跨境供应链和采购规划带来了新的变数。关税对不同产品类别和原料的适用程度不一，可能会影响活性药物原料药、辅料、製剂和专用给药装置的采购决策。事实上，製造商和经销商正在重新评估供应商多元化、合约条款和到岸成本模型，以确保供应的连续性和可预测的商业条款。

为应对关税带来的成本压力，一些行业相关人员正在加快生产能力的本地化，签订包含对冲条款的长期供应合同，或优化产品系列，优先选择受关税上涨影响较小的配方和包装形式。同时，采购者和医疗系统正在调整竞标结构和库存策略，以减轻短期价格波动的影响。供应链的透明度、替代采购管道以及与物流合作伙伴的协作规划，有助于确保病患在关税带来的不利影响下仍能获得医疗服务和保障医疗服务的连续性。

一个将治疗层级、给药途径、患者群体、疾病模式和分销管道与策略决策联繫起来的综合细分框架

透过精细的细分视角，将药物属性、患者需求和通路结合，从而明确支气管扩张治疗整体情况的治疗和商业策略。依药物类型分类，抗发炎药物（包括皮质类固醇和非类固醇抗发炎药物）主要针对慢性发炎环境，而抗生素则着重于抑制病原体和控制感染。支气管扩张剂依其作用机转分为长效和短效两种，以满足维持治疗和抢救治疗的需求，而黏液溶解剂则针对痰液黏度和清除机制。这种药理学分类有助于产品定位、处方讨论和组合方案。

给药途径决定了病人的依从性和用药方案。吸入疗法可最大限度地减少全身暴露，并支持居家治疗；而注射疗法（包括静脉注射和皮下注射）则用于病情严重加重或使用生物製药时。口服疗法因其使用方便和便于门诊管理，仍然是首选。患者的人口统计学特征进一步影响临床策略，因为成人、老年和儿童患者群体在併发症、耐受性指标和剂量需求方面存在差异。支气管扩张的分类有助于诊断和预后，进而影响治疗方法的选择和临床试验队列的筛选。最后，分销管道的细分——医院、线上和零售——决定了病患的就医途径、报销流程和病患援助计画的设计。

从策略区域视角探讨医疗保健系统、监管框架和医疗服务体系如何影响全球市场支气管扩张治疗的可近性和应用。

地理因素影响支气管扩张药物的临床应用、监管预期和商业化策略。美洲的医疗保健系统融合了以医院为主导的加护治疗和不断扩展的门诊服务，并高度重视真实世界证据的产生和多方相关人员的报销机制。该地区的临床网路和患者登记系统支援长期疗效追踪和可操作性研究，为报销文件和指南制定提供依据。

在欧洲、中东和非洲，监管协调工作和不同的报销环境要求临床叙述具有适应性，并需提供区域性的卫生经济学论点。在某些地区，呼吸系统药物（存在大量未满足的需求）的加速审批途径与严格的成本效益评估并存，这就需要量身定制的证据材料。在亚太地区，医疗基础设施的异质性、吸入技术的快速普及以及对本地生产能力的持续投入，都推动了独特的商业化策略。总而言之，这些区域差异凸显了灵活的市场推广计画和证据产生策略的重要性，这些计画和策略应反映区域支付方的优先事项和临床实践模式。

对支气管扩张治疗生态系中主要企业的竞争定位、创新路径和合作模式进行深入分析

支气管扩张治疗领域的竞争格局呈现出多元化的态势，既有经验丰富的肺科专家，也有专注于该领域的生物技术公司和大型多元化製药公司。领先企业通常透过专有的递送平台、生物製剂方法和抗菌药物管理策略来降低抗药性风险，从而实现差异化竞争。其他企业则专注于渐进式创新，例如将已知的活性分子改良为吸入剂或长效製剂，以提高耐受性和患者依从性；还有一些企业致力于研发First-in-Class靶点，以调节参与粘液分泌过多和气道重塑的特定炎症通路。

合作研究的重要性日益凸显，因为临床开发通常需要获得专门的註册、诊断能力和病患支援服务。研发人员与受託製造厂商之间的伙伴关係能够实现灵活的规模化生产和局部生产，而许可协议则被用于加速地域扩张。从商业性角度来看，那些将强大的临床差异化优势与完善的患者支持和医疗专业人员教育计画相结合的市场参与企业，更有可能获得处方权和临床应用。此外，投资于核准后证据产生和数位化依从性解决方案的机构，往往能够增强其长期价值提案。

为领导团队提供切实可行、影响深远的建议，以促进临床应用，增强韧性，并在支气管扩张治疗中为患者带来可衡量的益处。

对于寻求持续差异化优势和提升患者疗效的行业领导者而言，一系列切实可行的措施可以加速临床应用和商业性成功：首先，投资于评估病情加重负担、功能性结局和医疗资源利用情况的临床试验和真实世界试验，并以可靠的患者报告指标补充临床终点。其次，优化给药途径以减轻治疗负担。吸入式和易于使用的製剂能够减少全身暴露，符合临床医师的偏好和病患的遵从性。

接下来，透过供应商多元化、区域製造伙伴关係以及降低关税和物流中断风险的库存策略，增强供应链韧性。此外，设计整合医院、零售和线上药局通路的通路和病患支援路径，最大限度地提高医疗服务的可近性和连续性。最后，投入资源，调动包括临床专家、支付方证据团队和病患权益倡议团体在内的跨职能相关人员，共同建构一致的价值主张，推动其融入治疗方案和流程。采取这些协作措施，能够提高治疗方法创新转化为更好疗效和持续临床应用的可能性。

对混合方法研究方法的清晰描述，该方法结合了临床证据审查、监管分析、相关人员访谈和产品生命週期评估。

本研究采用混合方法，结合了临床文献评估、监管环境审查、相关人员访谈以及器材和製剂趋势分析。临床文献评估重点在于研究设计要素、终点选择以及各治疗层级的安全性概况。监管指南和公告的审查旨在识别不断变化的核准标准和上市后证据预期。来自临床医生、药品目录管理人员和供应链专家的主要定性意见有助于解读推广应用障碍和营运限制。

为了补充定性分析，产品和技术评估专注于交付系统、生产依赖性以及低温运输或处理要求。采用交叉检验技术来协调不同的资料点，确保结论的一致性。在适用情况下，也考虑了区域监管和报销的影响，以完善战略意义。这种混合方法为所提出的见解和建议奠定了坚实的基础，强调了其对临床开发、商业化和营运团队的实际应用价值。

总结全文强调，需要整合临床、营运和商业策略，才能在支气管扩张治疗中实现治疗价值。

要维持支气管扩张药物研发的持续势头，需要製定整合策略，将科学创新、营运韧性和相关人员合作相结合；而商业性成功则取决于灵活的分销模式、引人入胜的医保方案以及以患者为中心的疗效方面的显着改善。同样重要的是，要能够透过积极的规划和伙伴关係来应对供应链波动、监管差异和不断变化的临床预期。

最终，最有效的方案将治疗设计与实际应用相结合，并将临床疗效与有助于证明依从性、可近性和长期价值的机制相结合。那些秉持这种整体观点——投资于有针对性的循证实践、稳健的运营和持续的相关人员参与——的机构，最能将科学进步转化为患者照护和医疗系统绩效方面的切实改进。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 吸入脂质体抗生素治疗支气管扩张的疗效和安全性结果
  • 利用CFTR调变器治疗非囊肿纤维化支气管扩张症
  • 针对支气管扩张症嗜中性白血球发炎路径的单株抗体治疗方法的研发
  • 新型低分子量生物膜分散剂可增强支气管扩张患者的抗生素活性
  • 将基于生物标记的患者分层模型应用于支气管扩张症的个人化治疗
  • 真实世界临床试验对支气管扩张症长期疗效及健保报销的影响
  • 监管奖励和孤儿药认定可加速新型支气管扩张药物的核准
  • 抗微生物抗药性和抗菌药物管理在设计下一代支气管扩张药物的挑战

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 支气管扩张药物市场（依药物类型划分）

  • 抗发炎药
    • 皮质类固醇
    • 非类固醇消炎剂
  • 抗生素
  • 支气管扩张剂
    • 长效支气管扩张剂
    • 短效支气管扩张剂
  • 祛痰药

9. 支气管扩张药物市场（依给药途径划分）

  • 吸入
  • 注射
    • 静脉注射
    • 皮下
  • 口服

第十章：依患者特征分類的支气管扩张治疗市场

  • 成人版
  • 老头
  • 孩子们

第十一章 按支气管扩张类型分類的支气管扩张治疗市场

  • 圆柱形（管状）
  • 隆起的（囊性）

第十二章 支气管扩张药物市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 各地区支气管扩张药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 支气管扩张药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国支气管扩张药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AdvaCare Pharma
    • Armata Pharmaceuticals
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Cipla Limited
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline PLC
    • Glenmark Pharmaceuticals Limited
    • Insmed Incorporated
    • Lupin Limited
    • Merck & Co., Inc.
    • Mylan Inc. by Viatris Inc.
    • Nephron Pharmaceuticals Corporation
    • Novartis AG
    • Perrigo Company PLC
    • Pfizer Inc.
    • Renovion, Inc.
    • Sanofi SA
    • Steris Healthcare Pvt. Ltd.
    • Sun Pharmaceutical Industries Limited
    • Teva Pharmaceutical Industries Ltd.
    • Verona Pharma PLC
    • ZAMBON COMPANY SPA
    • Zydus Group
Product Code: MRR-B1685377A3D9

The Bronchiectasis Drugs Market is projected to grow by USD 3.13 billion at a CAGR of 9.46% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.52 billion
Estimated Year [2025] USD 1.65 billion
Forecast Year [2032] USD 3.13 billion
CAGR (%) 9.46%

A concise and authoritative orientation to bronchiectasis pharmacotherapy developments, clinical priorities, and the evolving framework for therapeutic innovation

Bronchiectasis has emerged from clinical obscurity to become a focal point for drug development, driven by improved diagnostic recognition, expanding therapeutic hypotheses, and a growing emphasis on quality-of-life outcomes. Recent years have seen a convergence of research efforts across anti-inflammatory strategies, targeted antimicrobial approaches, airway clearance modalities, and symptomatic bronchodilation, all informed by advances in imaging, sputum microbiology, and longitudinal patient registries. This combination of clinical insight and translational science has reshaped how clinicians and industry stakeholders view the disease as a treatable chronic condition rather than an inevitably progressive one.

Consequently, pipelines now reflect a blend of repurposed agents, novel molecular entities, and delivery-optimized formulations intended to address the multifactorial pathophysiology of bronchiectasis. Regulatory dialogues increasingly emphasize patient-reported outcomes and exacerbation reduction as meaningful endpoints, while payers and providers focus on therapies that demonstrably reduce healthcare utilization and improve daily functioning. As a result, strategic decision-making requires an integrated view of clinical evidence, therapeutic differentiation, and practical adoption barriers to translate scientific advances into sustainable patient benefit.

An incisive account of how targeted immunomodulation, therapeutic personalization, and delivery innovation are reshaping treatment paradigms for bronchiectasis

The therapeutic landscape for bronchiectasis is undergoing transformative shifts driven by targeted immunomodulation, precision antimicrobial stewardship, and innovations in inhalation delivery systems. First, the emergence of anti-inflammatory strategies that extend beyond broad corticosteroid use-incorporating selective pathway modulators and adjunctive agents-has reframed treatment paradigms to prioritize chronic inflammation control without unacceptable systemic exposure. This shift is coupled with a more nuanced appreciation of airway microbiome dynamics, prompting development of antibiotics and biologics that aim to reduce pathogenic burden while preserving microbial ecology.

Concurrently, device- and formulation-driven advances have reduced the friction of long-term therapy, with inhaled formulations and optimized nebulizer technologies enabling higher local drug concentrations and improved tolerability. On the regulatory and evidence front, stakeholders now place greater weight on patient-centered endpoints, including exacerbation frequency, functional capacity, and health-related quality of life, which in turn influences trial design and postmarketing value demonstration. Taken together, these shifts are fostering a more patient-centric, precision-oriented approach to bronchiectasis management that aligns clinical objectives with product innovation and adoption pathways.

A pragmatic exploration of how recent United States tariff dynamics are prompting supply chain resilience, sourcing adjustments, and procurement strategy shifts in respiratory therapeutics

Recent tariff developments in the United States have introduced a new variable into cross-border supply chains and procurement planning for respiratory pharmaceuticals. While tariffs are applied unevenly across product classes and raw material categories, they can influence sourcing decisions for active pharmaceutical ingredients, excipients, finished dosage forms, and specialized delivery devices. In practice, manufacturers and distributors are reassessing supplier diversification, client contractual terms, and landed-cost models to maintain supply continuity and predictable commercial terms.

In response to tariff-induced cost pressure, several industry participants have either accelerated localization of manufacturing capacity, negotiated longer-term supply contracts with hedging provisions, or optimized product portfolios to prioritize formulations and packaging formats that are less exposed to incremental duties. Buyers and health systems, in turn, are revisiting tender structures and inventory strategies to mitigate short-term price volatility. Crucially, these operational adjustments emphasize resilience: supply chain visibility, alternative sourcing, and collaborative planning with logistics partners help ensure that patient access and therapeutic continuity remain intact despite tariff-related headwinds.

A comprehensive segmentation framework linking therapeutic class, administration route, patient cohorts, disease morphology, and distribution channels to strategic decision-making

A refined segmentation lens clarifies therapeutic and commercial strategies across the bronchiectasis landscape by aligning drug attributes, patient needs, and distribution pathways. When classifying by drug type, anti-inflammatory agents-including corticosteroids and nonsteroidal anti-inflammatory agents-address the chronic inflammatory milieu, while antibiotics concentrate on pathogen suppression and infection control; bronchodilators are differentiated into long-acting and short-acting agents to meet both maintenance and rescue needs, and mucolytics target sputum viscosity and clearance mechanics. This pharmacologic taxonomy informs product positioning, formulary discussions, and combination regimens.

Route of administration drives adherence and delivery considerations: inhalation approaches minimize systemic exposure and support home-based therapy, injection routes-comprising both intravenous and subcutaneous options-are reserved for severe exacerbations or biologic therapies, and oral therapies remain central for ease of use and outpatient management. Patient demographics further nuance clinical strategy, as adult, geriatric, and pediatric populations present differing comorbidity profiles, tolerability windows, and dosing requirements. Disease subtype stratification between cylindrical (tubular) and varicose (cystic) bronchiectasis contributes diagnostic and prognostic context that can influence therapeutic choice and trial cohort selection. Finally, distribution channel segmentation across hospital pharmacies, online pharmacies, and retail pharmacies defines access touchpoints, reimbursement workflows, and patient support program design, all of which are essential for achieving meaningful uptake and sustained adherence.

A strategic regional perspective on how healthcare systems, regulatory frameworks, and delivery ecosystems shape bronchiectasis therapy access and adoption across global markets

Geographic contours shape clinical access, regulatory expectations, and commercialization approaches for bronchiectasis therapies. In the Americas, healthcare systems demonstrate a mix of centralized hospital-led care and expanding outpatient services, with strong emphasis on real-world evidence generation and multi-stakeholder payer engagements. Clinical networks and patient registries in this region support longitudinal outcome tracking and pragmatic studies that inform reimbursement dossiers and guideline development.

Across Europe, Middle East & Africa, regulatory harmonization efforts and diverse reimbursement environments necessitate adaptable clinical narratives and localized health economic arguments. In several jurisdictions, accelerated pathways for unmet-need respiratory therapies coexist with rigorous cost-effectiveness evaluation, requiring tailored evidence packages. In the Asia-Pacific region, heterogeneity in healthcare infrastructure, rapid adoption of inhalation technologies, and growing investment in local manufacturing capacity drive distinct commercialization strategies; partnerships with regional distributors and attention to cold-chain and logistics considerations can materially affect availability and uptake. Taken together, these regional differences underline the importance of flexible market entry plans and evidence generation strategies that reflect local payer priorities and clinical practice patterns.

An informed analysis of competitive positioning, innovation pathways, and collaborative models that define leading companies in the bronchiectasis therapeutics ecosystem

Competitive dynamics in bronchiectasis therapeutics reflect a mix of established respiratory specialists, specialty biotech firms, and larger diversified pharmaceutical companies. Key players often differentiate through proprietary delivery platforms, biologic modalities, or antimicrobial stewardship strategies that reduce resistance risk. Some organizations prioritize incremental innovation by reformulating known active molecules into inhaled or longer-acting forms, thereby improving tolerability and adherence, while others pursue first-in-class targets that modulate specific inflammatory pathways implicated in mucus hypersecretion and airway remodeling.

Collaboration is increasingly prominent, as clinical development often requires access to specialized registries, diagnostic capabilities, and patient support services. Partnerships between developers and contract manufacturing organizations enable flexible scale-up and localized production, and licensing agreements are used to accelerate geographic expansion. From a commercial perspective, market entrants that combine strong clinical differentiation with robust patient support and healthcare professional education programs are better positioned to secure formulary placement and clinical adoption. Moreover, organizations that invest in post-authorization evidence generation and digital adherence solutions tend to strengthen their long-term value propositions.

Practical, high-impact recommendations for leadership teams to accelerate clinical adoption, enhance resilience, and deliver measurable patient benefit in bronchiectasis care

For industry leaders seeking durable differentiation and patient impact, a set of pragmatic actions can accelerate clinical adoption and commercial success. First, prioritize evidence generation that directly addresses payer and clinician concerns: invest in trials and real-world studies that measure exacerbation burden, functional outcomes, and healthcare resource utilization, and complement clinical endpoints with robust patient-reported measures. Second, optimize delivery modalities to lower treatment burden; inhaled and user-friendly formulations that reduce systemic exposure will align with both clinician preference and patient adherence.

Next, strengthen supply chain resilience through supplier diversification, regional manufacturing partnerships, and inventory strategies that reduce vulnerability to tariff and logistics disruptions. Additionally, design distribution and patient support pathways that integrate hospital, retail, and digital pharmacy channels to maximize accessibility and continuity of care. Finally, invest in cross-functional stakeholder engagement-clinical champions, payer evidence teams, and patient advocacy groups-to create aligned value narratives that expedite inclusion in treatment protocols and formularies. These coordinated steps enhance the likelihood that therapeutic innovations translate into improved outcomes and sustained clinical uptake.

A transparent explanation of the mixed-methods research approach blending clinical evidence review, regulatory analysis, stakeholder interviews, and product lifecycle assessment

This research synthesis is grounded in a mixed-methods approach that combines clinical literature appraisal, regulatory landscape review, stakeholder interviews, and synthesis of device and formulation trends. Clinical literature was evaluated with attention to trial design elements, endpoint selection, and safety profiles across therapeutic classes. Regulatory guidance and public filings were examined to identify evolving approval criteria and postmarketing evidence expectations. Primary qualitative inputs from clinicians, formulary managers, and supply chain specialists informed interpretation of adoption barriers and operational constraints.

Complementing qualitative inputs, product and technology assessments focused on delivery systems, manufacturing dependencies, and cold-chain or handling requirements. Cross-validation techniques were used to reconcile disparate data points and ensure consistency of conclusions. Where applicable, sensitivity to regional regulatory and reimbursement variance was applied to refine strategic implications. This blended methodology provides a robust foundation for the insights and recommendations presented, emphasizing practical applicability for clinical development, commercialization, and operations teams.

A conclusive synthesis underscoring the need for integrated clinical, operational, and commercial strategies to realize therapeutic value in bronchiectasis care

Sustaining momentum in bronchiectasis therapeutics requires integrated strategies that bridge scientific innovation, operational resilience, and stakeholder alignment. The evolving evidence base supports a transition toward therapies that are both clinically differentiated and user-friendly, while commercial success will hinge on adaptable distribution models, compelling payer narratives, and demonstrable improvements in patient-centered outcomes. Equally important is the ability to navigate supply chain volatility, regulatory diversity, and shifting clinical expectations with proactive planning and partnership.

Ultimately, the most effective programs will align therapeutic design with real-world use, coupling clinical efficacy with mechanisms to support adherence, access, and long-term value demonstration. Organizations that embrace this holistic view-investing in targeted evidence, resilient operations, and sustained stakeholder engagement-will be best positioned to convert scientific advances into meaningful improvement in patient care and health system performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Efficacy and safety outcomes of inhaled liposomal antibiotics in bronchiectasis management
  • 5.2. Utilization of CFTR modulators repurposed for non-cystic fibrosis bronchiectasis therapy
  • 5.3. Development of monoclonal antibody treatments targeting neutrophilic inflammation pathways in bronchiectasis
  • 5.4. Emerging small molecule biofilm dispersal agents to enhance antibiotic activity in bronchiectasis patients
  • 5.5. Integration of biomarker-driven patient stratification models for personalized bronchiectasis drug therapy
  • 5.6. Impact of real-world evidence studies on long-term outcomes and payer reimbursement in bronchiectasis
  • 5.7. Regulatory incentives and orphan drug designations accelerating novel bronchiectasis treatment approvals
  • 5.8. Challenges of antimicrobial resistance and stewardship in designing next-generation bronchiectasis antibiotics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bronchiectasis Drugs Market, by Drug Type

  • 8.1. Anti-Inflammatory Agents
    • 8.1.1. Corticosteroids
    • 8.1.2. NSAIDs
  • 8.2. Antibiotics
  • 8.3. Bronchodilators
    • 8.3.1. Long-Acting Bronchodilators
    • 8.3.2. Short-Acting Bronchodilators
  • 8.4. Mucolytics

9. Bronchiectasis Drugs Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injection
    • 9.2.1. Intravenous
    • 9.2.2. Subcutaneous
  • 9.3. Oral

10. Bronchiectasis Drugs Market, by Patient Demographics

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Bronchiectasis Drugs Market, by Bronchiectasis Type

  • 11.1. Cylindrical (Tubular)
  • 11.2. Varicose (Cystic)

12. Bronchiectasis Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Bronchiectasis Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bronchiectasis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bronchiectasis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AdvaCare Pharma
    • 16.3.2. Armata Pharmaceuticals
    • 16.3.3. AstraZeneca PLC
    • 16.3.4. Bayer AG
    • 16.3.5. Boehringer Ingelheim International GmbH
    • 16.3.6. Cipla Limited
    • 16.3.7. F. Hoffmann-La Roche AG
    • 16.3.8. GlaxoSmithKline PLC
    • 16.3.9. Glenmark Pharmaceuticals Limited
    • 16.3.10. Insmed Incorporated
    • 16.3.11. Lupin Limited
    • 16.3.12. Merck & Co., Inc.
    • 16.3.13. Mylan Inc. by Viatris Inc.
    • 16.3.14. Nephron Pharmaceuticals Corporation
    • 16.3.15. Novartis AG
    • 16.3.16. Perrigo Company PLC
    • 16.3.17. Pfizer Inc.
    • 16.3.18. Renovion, Inc.
    • 16.3.19. Sanofi S.A.
    • 16.3.20. Steris Healthcare Pvt. Ltd.
    • 16.3.21. Sun Pharmaceutical Industries Limited
    • 16.3.22. Teva Pharmaceutical Industries Ltd.
    • 16.3.23. Verona Pharma PLC
    • 16.3.24. ZAMBON COMPANY S.P.A.
    • 16.3.25. Zydus Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRONCHIECTASIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 318. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 319. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 320. GCC BRONCHIECTASIS DRUGS MARKET SIZE, B